Influence of genetic variants of CYP2D6,CYP2C9,CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy

Background identified the polymorphisms of cyp2d6,cyp2c9,cyp2c19 and cyp3a4,within a rigorously selected population of pediatric patients with drug-resistant epilepsy. method the genomic dna of 23 drug-resistant epilepsy patients and 7 patients with good responses were analyzed. ten exons in these four genes were genotyped,and the drug concentrations in saliva and plasma were determined. results the relevant snps with pharmacogenomics relations were cyp2d6*2 (rs16947) decreased your activity and cyp2d6*4 (rs1065852),cyp2c19*2 (rs4244285) and cyp3a4*1b (rs2740574) by association with poor metabolizer. the strongest risk factors were found in the aa genotype and allele of snp rs3892097 from the cyp2d6 gene,followed by the alleles a and t of snps rs2740574 and rs2687116,respectively from cyp3a4. the most important concomitance was between homozygous genotype aa of rs3892097 and genotype aa of rs2740574 with 78.3% in drug-resistant epilepsy patients as compared to 14.3% in control patients. conclusion the results demonstrated the important role of the cyp 3a4*1b allelic variant as risk factor for developing drug resistance and cyp2d6,cyp2c19 snps and haplotypes may affect the response to antiepileptic drugs. © 2017